Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Sales and Divestitures (2016 - 2018)

Amicus Therapeutics filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $353442.0 for Q1 2018.

  • On a quarterly basis, Gains from Sales and Divestitures rose 7420.04% to $353442.0 in Q1 2018 year-over-year; TTM through Mar 2018 was $353442.0, a 7420.04% increase, with the full-year FY2017 number at $318200.0, up 12.88% from a year prior.
  • Gains from Sales and Divestitures hit $353442.0 in Q1 2018 for Amicus Therapeutics, up from $318200.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $842500.0 in Q4 2015 to a low of $4700.0 in Q1 2017.
  • Median Gains from Sales and Divestitures over the past 4 years was $246405.5 (2016), compared with a mean of $301757.4.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 66.54% in 2016 and later skyrocketed 7420.04% in 2018.
  • Amicus Therapeutics' Gains from Sales and Divestitures stood at $842500.0 in 2015, then plummeted by 66.54% to $281900.0 in 2016, then rose by 12.88% to $318200.0 in 2017, then grew by 11.08% to $353442.0 in 2018.
  • The last three reported values for Gains from Sales and Divestitures were $353442.0 (Q1 2018), $318200.0 (Q4 2017), and $210911.0 (Q3 2017) per Business Quant data.